FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004454292> ?p ?o ?g. }

• W2004454292 endingPage "396" @default.
• W2004454292 startingPage "392" @default.
• W2004454292 abstract "This study investigated the therapeutic effect of single-agent i.v. weekly Navelbine (vinorelbine), a semisynthetic vinca alkaloid, in women who had received no prior treatment for locally advanced or metastatic breast cancer. Of 68 patients entered into the study, 63 were adequate inclusions, assessable for toxicity and response by WHO criteria; the 5 patients who were not evaluated were excluded from analysis because they were found not to meet the eligibility criteria of the study. Navelbine was given as a weekly 30 mg/m2 short i.v. (20 minutes) infusion; treatment was continued until disease progression. The overall response rate was 44% (complete response 8%, partial response 36%). The response rate according to target was lymph nodes, 62.9%; liver, 50.0%; lung, 50.0%; skin, 37.5%; and primary tumor, 30.8%. The median duration of response was 17.9 weeks (range: 7–52 weeks). The median time to treatment failure was 12.9 weeks, and the median survival was 50.3 weeks. The 63 eligible patients received 501 cycles. The mean dose intensity was 76%. At least one episode of WHO grade 3/4 granulocytopenia was seen in 46% of the patients (13.6% of cycles). Significant nausea/vomiting was seen in only 5% of patients, corresponding to 1 % of cycles. Only 5% of patients developed WHO grade 3–4 constipation and grade 3 peripheral neuropathy was observed in 1.6% of patients. Alopecia was rare (6.3% of patients), and other side effects were uncommon. This study confirms that Navelbine has major single-agent antitumor activity as frontline therapy in advanced breast cancer. Given its excellent tolerance profile and low morbidity, it should be recommended for inclusion in first-line combination chemotherapy regimens." @default.
• W2004454292 created "2016-06-24" @default.
• W2004454292 creator A5007943787 @default.
• W2004454292 creator A5008798210 @default.
• W2004454292 creator A5015558382 @default.
• W2004454292 creator A5022840319 @default.
• W2004454292 creator A5026225932 @default.
• W2004454292 creator A5027396660 @default.
• W2004454292 creator A5031504621 @default.
• W2004454292 creator A5041487103 @default.
• W2004454292 creator A5043939766 @default.
• W2004454292 creator A5046437618 @default.
• W2004454292 creator A5051971718 @default.
• W2004454292 creator A5052371243 @default.
• W2004454292 creator A5079539008 @default.
• W2004454292 creator A5084536885 @default.
• W2004454292 creator A5088650996 @default.
• W2004454292 date "1995-10-01" @default.
• W2004454292 modified "2023-10-12" @default.
• W2004454292 title "Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer Chemotherapy" @default.
• W2004454292 doi "https://doi.org/10.1097/00000421-199510000-00006" @default.
• W2004454292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7572754" @default.
• W2004454292 hasPublicationYear "1995" @default.
• W2004454292 type Work @default.
• W2004454292 sameAs 2004454292 @default.
• W2004454292 citedByCount "74" @default.
• W2004454292 countsByYear W20044542922012 @default.
• W2004454292 countsByYear W20044542922013 @default.
• W2004454292 countsByYear W20044542922014 @default.
• W2004454292 countsByYear W20044542922019 @default.
• W2004454292 countsByYear W20044542922020 @default.
• W2004454292 countsByYear W20044542922021 @default.
• W2004454292 countsByYear W20044542922022 @default.
• W2004454292 crossrefType "journal-article" @default.
• W2004454292 hasAuthorship W2004454292A5007943787 @default.
• W2004454292 hasAuthorship W2004454292A5008798210 @default.
• W2004454292 hasAuthorship W2004454292A5015558382 @default.
• W2004454292 hasAuthorship W2004454292A5022840319 @default.
• W2004454292 hasAuthorship W2004454292A5026225932 @default.
• W2004454292 hasAuthorship W2004454292A5027396660 @default.
• W2004454292 hasAuthorship W2004454292A5031504621 @default.
• W2004454292 hasAuthorship W2004454292A5041487103 @default.
• W2004454292 hasAuthorship W2004454292A5043939766 @default.
• W2004454292 hasAuthorship W2004454292A5046437618 @default.
• W2004454292 hasAuthorship W2004454292A5051971718 @default.
• W2004454292 hasAuthorship W2004454292A5052371243 @default.
• W2004454292 hasAuthorship W2004454292A5079539008 @default.
• W2004454292 hasAuthorship W2004454292A5084536885 @default.
• W2004454292 hasAuthorship W2004454292A5088650996 @default.
• W2004454292 hasConcept C121608353 @default.
• W2004454292 hasConcept C126322002 @default.
• W2004454292 hasConcept C141071460 @default.
• W2004454292 hasConcept C2775930923 @default.
• W2004454292 hasConcept C2776553716 @default.
• W2004454292 hasConcept C2776694085 @default.
• W2004454292 hasConcept C2776755627 @default.
• W2004454292 hasConcept C2778239845 @default.
• W2004454292 hasConcept C2778822529 @default.
• W2004454292 hasConcept C2779429289 @default.
• W2004454292 hasConcept C2780350996 @default.
• W2004454292 hasConcept C2780580376 @default.
• W2004454292 hasConcept C2780852908 @default.
• W2004454292 hasConcept C31760486 @default.
• W2004454292 hasConcept C530470458 @default.
• W2004454292 hasConcept C71924100 @default.
• W2004454292 hasConcept C90924648 @default.
• W2004454292 hasConceptScore W2004454292C121608353 @default.
• W2004454292 hasConceptScore W2004454292C126322002 @default.
• W2004454292 hasConceptScore W2004454292C141071460 @default.
• W2004454292 hasConceptScore W2004454292C2775930923 @default.
• W2004454292 hasConceptScore W2004454292C2776553716 @default.
• W2004454292 hasConceptScore W2004454292C2776694085 @default.
• W2004454292 hasConceptScore W2004454292C2776755627 @default.
• W2004454292 hasConceptScore W2004454292C2778239845 @default.
• W2004454292 hasConceptScore W2004454292C2778822529 @default.
• W2004454292 hasConceptScore W2004454292C2779429289 @default.
• W2004454292 hasConceptScore W2004454292C2780350996 @default.
• W2004454292 hasConceptScore W2004454292C2780580376 @default.
• W2004454292 hasConceptScore W2004454292C2780852908 @default.
• W2004454292 hasConceptScore W2004454292C31760486 @default.
• W2004454292 hasConceptScore W2004454292C530470458 @default.
• W2004454292 hasConceptScore W2004454292C71924100 @default.
• W2004454292 hasConceptScore W2004454292C90924648 @default.
• W2004454292 hasIssue "5" @default.
• W2004454292 hasLocation W20044542921 @default.
• W2004454292 hasLocation W20044542922 @default.
• W2004454292 hasOpenAccess W2004454292 @default.
• W2004454292 hasPrimaryLocation W20044542921 @default.
• W2004454292 hasRelatedWork W1968731610 @default.
• W2004454292 hasRelatedWork W1978526423 @default.
• W2004454292 hasRelatedWork W1991910236 @default.
• W2004454292 hasRelatedWork W1996178784 @default.
• W2004454292 hasRelatedWork W2080201768 @default.
• W2004454292 hasRelatedWork W2163467469 @default.
• W2004454292 hasRelatedWork W2416053208 @default.
• W2004454292 hasRelatedWork W2418393176 @default.
• W2004454292 hasRelatedWork W2607246766 @default.
• W2004454292 hasRelatedWork W2809305836 @default.

• next